汇仁HUIREN品牌怎么样 申请店铺

我要投票 汇仁HUIREN在乌鸡白凤丸行业中的票数:8 更新时间:2024-11-21
汇仁HUIREN是哪个国家的品牌?「汇仁HUIREN」是 汇仁集团有限公司旗下著名品牌。该品牌发源于江西,由创始人陈冰郎在1996期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。
汇仁HUIREN怎么样

汇仁集团创建于1992年,是一家按健康产业链拓展,产学研相结合,科工贸一体化,集成式发展的中国大型医药企业集团。总部位于历史名城江西南昌,现有员工4000余人,总占地面积约80万平方米,总资产超过20亿元。

汇仁集团秉承“仁者爱人”的核心理念,走出了一条独具特色的健康产业的发展之路,企业综合经济实力快速提升,2008年销售收入突破42亿元。跻身于江西省工业竞争力企业、中国工业行业排头兵企业、中国影响力民营企业等行列。“汇仁”商标被评为“驰名保护”和“中国医药行业影响力品牌”。集团总裁陈年代连续当选为十届、十一届全国人民代表大会代表。

汇仁集团坚持“致力振兴民族医药”和“科技是第一生产力”的发展观念,投巨资在中国药谷——上海张江高科技园区建设国家级研发中心,中心拥有向全国开放、国内规模最大的中试平台和一大批国际领先水平的仪器设施。先后引进了博士生导师、博士后、博士等二十多位高层次医药科研人才并建立了博士后工作站。几年来,完成了数十项药品研究开发任务,承担了十多项国家九五、十五科技攻关项目及多项国家级科研课题,与国家科技部生命科学发展中心、中国中医研究院、中国医药研究开发中心、中国医学科学院药用植物研究所、北京大学、中国药科大学、上海中医药大学等国内著名研究机构和院校保持良好的研究开发合作关系并取得了一大批研究成果。2005年,汇仁又在英国牛津科技园建立了欧洲研发中心。

强大的研发能力保证了汇仁产品的高品质和源源不断地推出疗效确切、价格低廉深受消费者欢迎的新产品。现在,汇仁已形成补益类、妇科儿科类、抗生素类、消化系统类、循环系统类中成药和化学药等10多个系列,9个剂型100多个规格的产品群。其中有10个产品拥有国家发明专利。

在全国,汇仁共有46个品种中药材GAP基地,总面积15000亩。按GAP要求建设的高标准、现代化的中药饮片厂可年产中药饮片15000吨。

2001年后,汇仁先后在江西、上海、郑州、深圳、哈尔滨等地收购和兴建了6家医药公司。位于江西南昌高新区的汇仁医药商业建有中部地区规模最大,配套设施最完备的医药仓储物流中心。短短的几年,汇仁医药商业已经雄踞江西医药商业首位,上海汇仁医药也已跻身上海医药商业前10名。

汇仁—一个伴随国家改革开放进程诞生发展起来的新兴企业。汇仁—一个融合中国人文传统与现代医药科技内涵的民族品牌。将继续秉承“仁者爱人”的核心理念,深耕中华大地,阔步走向世界。

Huiren group, founded in 1992, is a large pharmaceutical enterprise group in China, which is based on the development of health industry chain, the combination of production, learning and research, the integration of science, industry and trade, and the integrated development. Headquartered in Nanchang, Jiangxi, a historic city, with more than 4000 employees, the company covers an area of about 800000 square meters and total assets of more than 2 billion yuan. Huiren group adheres to the core concept of "benevolent people love others" and has embarked on a unique road to the development of health industry. The comprehensive economic strength of the enterprise has been improved rapidly. In 2008, its sales revenue exceeded 4.2 billion yuan. It has become one of the industrial competitive enterprises in Jiangxi Province, the leader of Chinese industrial industry, and the influential private enterprises in China. "Huiren" trademark is rated as "well-known protection" and "influential brand of Chinese pharmaceutical industry". Chen Shi, President of the group, was elected as the representative of the 10th and 11th National People's Congress. Huiren group adheres to the development concept of "striving to revitalize national medicine" and "science and technology is the first productivity". It has invested heavily in the construction of a national R & D center in Shanghai Zhangjiang High Tech Park, China Pharmaceutical valley. The center has the largest pilot test platform open to the whole country and a large number of international leading level instruments and facilities. More than 20 high-level medical research talents, including doctoral supervisor, postdoctoral and doctor, have been introduced and a postdoctoral workstation has been established. In recent years, it has completed dozens of drug research and development tasks, undertaken more than ten national science and technology research projects during the Ninth Five-Year Plan and the Tenth Five-Year Plan and many national scientific research projects, and cooperated with the life science development center of the Ministry of science and technology of the people's Republic of China, China Academy of traditional Chinese medicine, China Pharmaceutical Research and development center, Institute of medicinal plants of the Chinese Academy of Medical Sciences, Peking University, China Pharmaceutical University, Shanghai University of traditional Chinese medicine Many famous research institutions and colleges in China have maintained a good cooperative relationship in research and development and achieved a large number of research results. In 2005, Huiren established a European R & D center in Oxford Science Park, UK. The strong R & D ability ensures the high quality of Huiren products and continuously launch new products with precise curative effect and low price, which are popular with consumers. Now, Huiren has formed more than 10 series of products, including tonics, gynecology and pediatrics, antibiotics, digestive system, circulation system Chinese patent medicine and chemical medicine, and more than 100 specifications of 9 dosage forms. Among them, 10 products have national invention patents. In China, Huiren has 46 kinds of gap bases of traditional Chinese medicine with a total area of 15000 mu. According to gap requirements, the high standard and modern Chinese Herbal Pieces Factory can produce 15000 tons of Chinese herbal pieces per year. After 2001, Huiren successively acquired and built 6 pharmaceutical companies in Jiangxi, Shanghai, Zhengzhou, Shenzhen, Harbin and other places. Huiren pharmaceutical business, located in Nanchang high tech Zone, Jiangxi Province, has the largest medical storage and logistics center in the central region and the most complete supporting facilities. In just a few years, Huiren pharmaceutical business has ranked first in Jiangxi pharmaceutical business, and Shanghai Huiren pharmaceutical has also ranked in the top 10 of Shanghai Pharmaceutical business. Huiren - a new enterprise born and developed along with the process of national reform and opening up. Huiren is a national brand that integrates the Chinese cultural tradition and modern medical science and technology. We will continue to adhere to the core concept of "benevolent people love one another", deeply cultivate the land of China and stride towards the world.

本文链接: https://brand.waitui.com/ba570b826.html 联系电话:0791-85762481

千城特选小程序码

7×24h 快讯

拼多多:第三季度营收增速环比下降,将坚定高质量发展战略应对竞争挑战

36氪获悉,拼多多发布2024年第三季度财报。财报显示,本季度拼多多营收达到994亿元,与上个季度相比,营收的增速有所放缓。业内分析认为,一方面是因为电商行业的竞争依然激烈,另一方面是平台的“百亿减免”等举措影响了短期的财报表现。“为了应对行业竞争,我们将坚定地执行高质量发展战略,继续实行‘减免+扶持’的举措,持续完善平台及产业生态,为供需两侧带来更大的普惠。”拼多多陈磊表示。

2小时前

拼多多:第三季度利润环比下降22%,将长期投入“新质供给”“电商西进”战略

36氪获悉,拼多多发布2024年第三季度财报。财报显示,本季度拼多多利润达到250亿元,环比下降22%。过去这个季度,拼多多先后推出“百亿减免”“电商西进”“新质商家扶持计划”等重磅举措,持续扩大对生态建设的投资,一定程度上影响了短期的财报表现。拼多多陈磊表示,在财务数据之外,我们更加看重生态投资带来的长期价值,未来几个季度,拼多多将继续投入“新质供给”“电商西进”等战略,给用户、商家及产业带来更长远的回报。

2小时前

莎普爱思:股东拟合计减持不超5%公司股份

36氪获悉,莎普爱思公告,股东陈德康持有公司12.39%股份,上海景兴实业投资有限公司持有公司4.7%股份。陈德康计划减持公司股份数量合计不超过758.32万股,即不超过公司总股本的2%。上海景兴计划减持公司股份数量合计不超过1137.48万股,即不超过公司总股本的3%。

2小时前

永杰新材上交所主板IPO申请获证监会同意注册批复

36氪获悉,证监会下发关于同意永杰新材料股份有限公司首次公开发行股票注册的批复,同意该公司首次公开发行股票的注册申请。根据招股书,该公司拟在上交所主板上市,公司专业从事铝板带箔的研发、生产与销售,产品主要包括铝板带和铝箔两大类。

2小时前

东方电缆:公司及子公司近期中标合计约40亿元海底电缆项目

36氪获悉,东方电缆公告,公司及全资子公司东方海工院近期收到相关通知书,确认公司及东方海工院联合体为相关项目中标人。其中,直流海底电缆项目中标金额约15.14亿元,交流海底电缆项目中标金额合计约24.72亿元,以上项目合计中标金额约40亿元。同日公告,公司拟以自有资金投资建设东方中央研究院·总部项目,项目总投资金额约为5.54亿元。

2小时前

本页详细列出关于汇仁HUIREN的品牌信息,含品牌所属公司介绍,汇仁HUIREN所处行业的品牌地位及优势。
咨询